Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071753 | 0.74 | TRPM5 (0.39) | TRPM5CA12CA9HDAC4 | |
| SCHEMBL910839 | 0.74 | KDM4E (0.39) | TRPM5 | |
| SCHEMBL5439074 | 0.74 | CYP3A4 (0.39) | TRPM5 | |
| SCHEMBL658867 | 0.71 | — | — | |
| SCHEMBL30127632 | 0.71 | — | — | |
| SCHEMBL30129737 | 0.70 | ALDH1A1 (0.46) | TRPM5 | |
| SCHEMBL11382202 | 0.70 | ALDH1A1 (0.46) | TRPM5 | |
| SCHEMBL19302444 | 0.69 | CYP2A6 (0.52) | TRPM5 | |
| SCHEMBL13913279 | 0.69 | GABRA1 (0.39) | TRPM5 | |
| SCHEMBL17469029 | 0.69 | TRPM5 (0.39) | TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129896-A1 | INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3860717-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020072656-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072656-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
| WO-2014159218-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-0454621-B1 | Nematicide agents | NOVARTIS AG (CH) | 2000-07-12 | — | — | EP | disclosed |
| US-5447945-A | Controlling or preventing nematocidal attack on cultivated plants with nitro- or halo-substituted benzisothiazoles | CIBA-GEIGY CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| US-5169951-A | PROCESS FOR PREPARING NEMATICIDAL COMPOSITIONS | CIBA-GEIGY CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0454621-A2 | Nematicide agents | CIBA-GEIGY AG (CH) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | NOS1 3407/4885TRPM5 869/4885BACE1 1/4885 |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | NOS1 3981/4885TRPM5 4032/4885BACE1 4533/4885 |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS1 3681/4885TRPM5 941/4885BACE1 1/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | NOS1 536/4885TRPM5 1678/4885BACE1 828/4885 |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | DPYD, KRAS, ABL1 | NOS1 3981/4885TRPM5 4032/4885BACE1 4533/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | NOS1 3981/4885TRPM5 4032/4885BACE1 4533/4885 |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | NOS1 2527/4885TRPM5 4792/4885BACE1 1997/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | NOS1 3407/4885TRPM5 869/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.